Acquisition-driven expansion Novan has recently acquired EPI Health, expanding its commercial infrastructure, sales reach across 42 territories, and a broader product portfolio including plaque psoriasis, rosacea, acne, and dermatoses. This creates opportunities to cross-sell and upsell across dermatology specialties and leverage established sales channels.

Pipeline leverage The company’s proprietary NITRICIL nitric oxide platform suggests potential collaboration or licensing opportunities for novel dermatology therapies beyond current candidates, opening doors for co-development, out-licensing, or strategic partnerships with pharma and biotech companies seeking nitric oxide-based solutions.

Targeted viral derm SB206 berdazimer gel for molluscum contagiosum positions Novan in a niche antiviral dermatology space with a defined patient population and payer considerations. This focus can be expanded to other viral skin conditions where topical antivirals are sought, presenting product- and market-entry opportunities.

Commercial footprint Post-acquisition staffing includes a sales force covering 42 territories, enhanced by EPI Health’s marketing and market access teams. There is potential to optimize geographic penetration, accelerate launches of near-term product candidates, and optimize payer access strategies to improve reimbursement and patient access.

Financial traction With revenue in the mid-range and a recent $15M investment plus DIP financing tied to a broader strategic cap table change, there may be opportunities to structure new partnerships, licensing deals, or co-commercialization arrangements that align with Novan’s cash preservation goals while expanding product reach.